Fulcrum therapeutics to participate at the leerink partners global biopharma conference

Cambridge, mass., march 05, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (the “company”) (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the leerink partners global biopharma conference, being held in miami, fl on wednesday, march 13, 2024 at 9:20 a.m. et. management will also participate in one-on-one investor meetings.
FULC Ratings Summary
FULC Quant Ranking